Safeguarding women from recurring UTIs.
A long-term, comfortable solution with a novel bladder drug delivery platform.
SEED INVESTORS
ENDORSED BY KOLS AT
TREND
Over 2.5M US women suffer from recurrent UTIs each year.
RECURRENT URINARY TRACT INFECTIONS
rUTIs: 3-7+ UTIs in a single year
3.5% of post-menopausal women
Affects their entire life, like migraines
No long-term, easy treatments exist
PROBLEM
Current rUTI treatments fail both patients and providers.
2+ Gal Hâ‚‚O/day
Supplements
Probiotics
Creams
Antibiotics
Endless bathroom trips
Ineffective for rUTIs
Ineffective for rUTIs
Low patient usage (gross)
Punishing side effects
3-5 DOCTOR VISITS PER YEAR
Current treatments only temporary
Problem isn’t solved in the long-term
Huge emotional strain on patients and MDs
SOLUTION
Safeguarding women from recurring UTIs.
Novel Delivery Approach
Lasts 30+ days
Floats Comfortably
5-min Procedure
Naturally Eliminated
90% Looking for A Better Solution
GO TO MARKET
Initial beachhead of rUTIs; platform easily adapted for markets and diseases.
Beachhead Market
RECURRENT UTIS (US)
Launch
2.5M
US Women
3.5% of 72M
$7.5B TAM
RECURRENT UTIS (EU)
EU Expansion
5.6M
EU Women
3.5% of 159.9M Women 45+
+$16.8B
OVERACTIVE BLADDER (US)
Drug Expansion
2.3M
US Adults
+$6.9B
2.3M fail second-line therapies, only 300k brave third-line therapy
BLADDER CANCER (US)
Drug Expansion
~360k
US Patients
+$2B
Safeguarding women from recurring UTIs.
A long-term, comfortable solution with a novel bladder drug delivery platform.
Defensible and patented novel approach
Perfectly crafted to be market dominant
Enormous growing (and aging) market
Multiple fields waiting for new solutions